ArticleJournal of microbiological methods2009
Monoclonal antibodies specific for Candida albicans Als3 that immunolabel fungal cells in vitro and in vivo and block adhesion to host surfaces.
Article in Journal of microbiological methods, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 69 citations in OpenAlex.
- MUC16-dependent Renal Vascular Adhesion of Candida Promotes Tissue Invasion and Predicts Clinical Outcome in Candidemia.Research square · 2026Article
- Increased fungal burden in the gastrointestinal tract of brain-dead organ donors.Microbiology spectrum · 2025Article
- Identification of two anti-mBio · 2024Article
- COVID-19-associated fungal infections.Nature microbiology · 2022Review
- Development and Use of a Monoclonal Antibody Specific for theFrontiers in cellular and infection microbiology · 2022Article
- The prophylactic effects of monoclonal antibodies targeting the cell wall Pmt4 protein epitopes ofFrontiers in microbiology · 2022Article
- Assessing Als3 Peptide-Binding Cavity and Amyloid-Forming Region Contributions toFrontiers in cellular and infection microbiology · 2022Article
- Development and validation of monoclonal antibodies specific for Candida albicans Als2, Als9-1, and Als9-2.PloS one · 2022Article
- The Role of B-Cells and Antibodies againstVaccines · 2021Review
- Article
- Anandamide prevents the adhesion of filamentous Candida albicans to cervical epithelial cells.Scientific reports · 2020Article
- Pursuing Advances in DNA Sequencing Technology to Solve a Complex Genomic Jigsaw Puzzle: The Agglutinin-Like Sequence (Frontiers in microbiology · 2020Article
- Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Antigen I/II mediates interactions between Streptococcus mutans and Candida albicans.Molecular oral microbiology · 2018Article
- Current trends to control fungal pathogens: exploiting our knowledge in the host-pathogen interaction.Infection and drug resistance · 2018Review
- Article
- S. oralis activates the Efg1 filamentation pathway in C. albicans to promote cross-kingdom interactions and mucosal biofilms.Virulence · 2017Article
- Editorial: Vaccines, Immunotherapy and New Antifungal Therapy against Fungi: Updates in the New Frontier.Frontiers in microbiology · 2017Article
- Candida albicans Agglutinin-Like Sequence (Als) Family Vignettes: A Review of Als Protein Structure and Function.Frontiers in microbiology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Two monoclonal antibodies (MAbs) were raised against the Candida albicans cell-surface glycoprotein Als3 using the N-terminal domain of the protein as the immunogen. ELISA was used to demonstrate the specificity of the MAbs for the Als3 fragment, but not for the corresponding N-terminal domain fragments from other proteins in the Als family. The anti-Als3 MAbs immunolabeled the surface of germ tubes from a diverse collection of wild-type C. albicans isolates, but did not label yeast cells, an als3Delta/als3Delta deletion mutant strain, nor isolates of other Candida species associated with human disease. Als3 was visualized readily in fresh and formalin-fixed, paraffin-embedded kidney tissue from a murine model of candidiasis. The anti-Als3 MAbs were also useful for immunogold electron microscopy and Western blotting. Both MAbs blocked C. albicans adhesion to vascular endothelial cells and buccal epithelial cells. These versatile MAbs are a valuable addition to the reagents available to study C. albicans cell surface dynamics and interaction of the fungus with host cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.